Pro-Pharmaceuticals of Newton, MA, announced today that it got the go-ahead from the FDA to treat one breast cancer patient with its lead drug candidate, Davanat. The drug, a carbohydrate polymer currently in Phase II trials for colorectal and biliary cancers, is designed to be used in combination with other cancer treatments.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
